Pricing Log in Create free account
Friday 6 November 2026 Export SHC’s income statement to Excel — free account

Sotera Health Company

SHC Healthcare Diagnostics & Research

Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.

Revenue
+4.36%
EPS
+20.1%
Free cash flow
+65.0%
Total debt
+0.14%

Quarter to September 2026, against a year earlier

15.88 0.01 +0.06%
Market cap
$4.5B
P/E
26.3×
Fwd P/E
26.4×
Dividend yield
—
F-score
7/9
Altman Z
1.76
Beneish M
−2.75
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1,165.56
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 3 — — 2 — 2 — — 2 — — —
Insider Ownership 2.32%

Capital & Financial Ratios $m

Size
Market Cap 4,530.00
Revenue ttm 1,229.75
Net income ttm 173.47
Free cash flow ttm 135.43
Net debt Q 1,828.30
Valuation
P/E 26.27
Forward P/E 26.40
Price / sales 3.69
Forward P/S Powerpack
Price / FCF 33.51
Price / book 6.19 (above 6: high)
Financial health
Current ratio Q 3.13 (at or above 1.5: strong)
Debt / equity Q 3.06 (above 2: weak)
Interest coverage Q 3.33
Growth
Revenue growth Q +4.36% (above 0%: growing)
Operating income growth Q +2.22% (above 0%: growing)
EPS, this year +14.35%
EPS, next year A +8.29%
Revenue, next year A +7.17%
EPS, past 5 yrs —
EPS, next 5 yrs A +10.57%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.2×, against a ten-year median of 5.9×; over the ten years it ranged from 3.6× in 2022 to 11.5× in 2020.
P/E against its own 10 years 6.60%
10-year low 10-year high
P/S against its own 10 years 26.94%
10-year low 10-year high
P/B against its own 10 years 5.38%
10-year low 10-year high
EV/Sales against its own 10 years 20.72%
10-year low 10-year high
EV/FCF against its own 10 years 18.71%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 302 279 346 412
Receivables 153 147 147 162
Inventory 48 49 54 50
Other — — — —
557 526 613 701
2023 2024 2025 Q'26
Payables 71 55 78 80
ST’ Debt 5 15 14 14
Other — — — —
231 191 250 224

Compound Annual Growth %

10y 5y 3y
Sales — 7.30% 5.05%
Cash Flow — 18.95% 1.10%
Earnings — 0.00% 0.00%
Book Value — 5.92% 20.05%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.27 Actual 0.29

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.24 0.26 Beat by 0.02
Q1 FY26 0.17 0.18 Beat by 0.01
Q2 FY26 0.24 0.26 Beat by 0.02
Q3 FY26 0.27 0.29 Beat by 0.02
Q4 FY26 0.27 — Reports 23 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.09 0.19 0.20 — —
’25 (0.05) 0.03 0.17 0.12 0.27
’24 0.02 0.03 0.06 0.04 0.16
’23 0.01 0.08 (0.05) 0.14 0.18
’22 0.11 0.11 0.09 (1.14) (0.83)
’21 0.04 0.15 0.10 0.13 0.41
’20 (0.01) 0.03 0.00 (0.17) (0.16)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 280 321 325 — —
’25 255 294 311 303 1,164
’24 248 277 285 290 1,100
’23 221 255 263 310 1,049
’22 237 267 249 252 1,004
’21 212 252 226 241 931
’20 188 213 200 217 818
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 29 88 111 — —
’25 56 57 71 103 287
’24 10 61 97 56 224
’23 34 (337) 42 113 (148)
’22 50 58 68 102 278
’21 56 78 81 66 282
’20 6 47 46 22 121
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (17) 42 58 — —
’25 36 26 35 52 149
’24 (25) 19 61 (10) 45
’23 (11) (390) (10) 48 (363)
’22 14 22 29 30 96
’21 35 54 65 25 179
’20 (7) 37 36 2 67
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 746 778 818 931 1,004 1,049 1,100 1,164 1,230 +6.6% 1,247 1,320 1,398 +6.3%
Gross margin, % — — 47.88 50.81 54.22 55.68 55.50 55.00 54.73 55.48 54.62 +7.6 pt
EBT — — 24 (1) (39) 176 (243) 106 114 148 275 +29.4%
EBT margin, % — — 3.25 (0.12) (4.75) 18.86 (24.22) 10.10 10.35 12.68 22.35 +9.4 pt
Net income — 0 (6) (20) (37) 117 (234) 51 44 78 173 n/m
Per share, $
Per share, $ Revenue — — 3.21 3.35 3.44 3.34 3.58 3.73 3.89 4.10 4.30 +3.5%
Earnings — — (0.03) (0.09) (0.16) 0.41 (0.83) 0.18 0.16 0.27 0.60 n/m
Cash flow — — 0.51 0.64 0.51 1.01 0.99 (0.53) 0.79 1.01 1.16 +10.1%
Capex — — (0.31) (0.25) (0.23) (0.37) (0.65) (0.76) (0.63) (0.49) (0.69) +6.5%
Free cash flow — — 0.20 0.39 0.28 0.64 0.34 (1.29) 0.16 0.53 0.47 +14.6%
Book value — — 0.20 (2.76) 1.91 2.10 1.25 1.58 1.43 2.13 2.56 +40.7%
Shares, m — — 232 232 238 279 280 281 283 284 285 +2.9%
Valuation, ×
Valuation, × P/E — — 4,648.15 4,648.15 0.00 56.07 0.00 93.06 91.20 65.33 26.27 1,200.2
P/S — — 7.32 7.32 8.50 7.06 2.32 4.49 3.52 4.30 3.69 5.6
P/B — — 0.00 0.00 15.30 11.22 6.66 10.61 9.55 8.27 6.19 7.7
EV/Sales — — 10.94 10.94 10.66 8.87 3.92 6.34 5.37 5.93 5.18 7.9
EV/FCF — — 55.56 55.56 130.05 46.07 41.20 (18.34) 131.01 46.23 47.01 60.9
Cash, $m
Cash, $m Operating cash flow — — 120 149 121 282 278 (148) 224 287 332 +13.3%
Capex — — (73) (57) (54) (102) (182) (215) (179) (138) (196) +9.6%
Free cash flow — — 47 92 67 179 96 (363) 45 149 135 +18.0%
Balance, $m
Balance, $m Working capital — — 169 128 174 185 (147) 327 335 364 477 +11.5%
Net debt — — 2,140 2,784 1,768 1,687 1,605 1,947 2,039 1,888 1,828 (1.8%)
Shareholders’ equity — — 45 (641) 455 586 350 444 405 606 733 +44.8%
Returns, %
Returns, % ROA — — (0.43) (0.79) (1.45) 4.21 (7.91) 1.64 1.43 2.46 5.28 +2.9 pt
ROIC — — 2.31 5.35 5.79 7.06 7.94 7.23 7.61 9.07 9.80 +6.8 pt
ROE — — 1.96 7.00 41.40 22.46 (49.89) 12.87 10.45 15.42 27.03 +13.5 pt
People
People Employees — — — 2,900 3,000 3,000 3,000 3,000 3,000 3,000 — +0.6%
Revenue/emp, $m — — 0.00 0.27 0.27 0.31 0.33 0.35 0.37 0.39 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Sotera Health Company vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
QGEN QIAGEN N.V. $10.5B 26.1× 26.0× +0.28% (above 0%: growing) +7.94% (above 0%: growing) +30.45% (above 0%: growing) 63.62% 24.75% Compare
RDNT RadNet, Inc. $6.1B — (loss-making) 1,050× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
GRAL GRAIL, Inc. $5.3B — (loss-making) — (loss-making) +3.71% (above 0%: growing) n/m −24.90% (below 0%: shrinking) 0.00% (385.29%) Compare
BLLN BillionToOne, Inc. $5.3B 88.7× 146× +47.24% (above 0%: growing) +164.29% (above 0%: growing) +9.25% (above 0%: growing) 70.86% 8.96% Compare
SHC Sotera Health Company $4.5B 26.3× 26.4× +4.36% (above 0%: growing) +20.12% (above 0%: growing) +64.98% (above 0%: growing) 55.65% 34.98%
ADPT Adaptive Biotechnologies Corporation $4.3B — (loss-making) — (loss-making) −10.72% (below 0%: shrinking) −66.67% (below 0%: shrinking) +201.86% (above 0%: growing) 76.24% (0.54%) Compare
CDNA CareDx, Inc. $4.0B 30.9× 36.2× +39.29% (above 0%: growing) +1,133.33% (above 0%: growing) −68.62% (below 0%: shrinking) 71.09% 5.82% Compare
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%) Compare
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92% Compare
Median of peers $4.8B 28.5× 45.2× +13.26% +35.22% −17.26% 67.10% 6.08%

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 8 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 10.66m 16.71m 64.00
2024 10.39m 5.07m 54.00
2023 9.70m 31.19m 67.00
2022 16.66m 5.91m 33.00
2021 2.20m (2.36m) 94.00

Ownership

Directors and executive officers, together 15.36%
Darsana Capital Partners LP 8.77%
Sculptor Capital LP 7.36%
Sessa Capital LP 7.21%
Ruoxi Chen 6.73%
James C. Neary 6.73%
Robert B. Knauss 6.72%
Investment funds and entities affiliated with Warburg Pincus 6.70%
BlackRock, Inc. 6.22%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Sotera Health Company (SHC) Latest News

5 Nov

Impact 3 · · Simply Wall St.

3 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat
Impact 3 · · StockStory
Impact 3 · · GlobeNewswire

19 Oct

Impact 3 · · StockStory

9 Oct

Impact 4 · · Simply Wall St.

15 Sep

Impact 4 ·

16 Aug

Impact 3 ·

15 Aug

Impact 3 ·

13 Aug

Impact 3 · · The Motley Fool transcript

10 Aug

Impact 4 ·

9 Aug

Impact 4 ·

7 Aug

Impact 3 ·
Impact 3 · · MarketBeat

6 Aug

Impact 4 ·
Impact 3 · · Moby
Impact 3 ·

26 May

Impact 3 · · Simply Wall St.

25 May

Impact 4 · · Simply Wall St.

22 May

Impact 3 · · StockStory

15 May

Impact 3 · · StockStory

13 May

Impact 4 · · Simply Wall St.

5 May

Impact 4 · · Moby
Impact 4 · · Zacks
Impact 4 · · Zacks
Impact 4 · · StockStory
Impact 3 · · MarketBeat

SHC metrics, ten years each

stockrow.com/SHC · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com